References
- Gerdes J, Schwab U, Lemke H, . Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983;31:13–20.
- Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182:311–322.
- Brown DC, Gatter KC. Ki67 protein: the immaculate deception? Histopathology 2002;40:2–11.
- Bryant RJ, Banks PM, O'Malley DP. Ki67 staining pattern as a diagnostic tool in the evaluation of lymphoproliferative disorders. Histopathology 2006;48:505–515.
- Szczuraszek K, Mazur G, Jelen M, . Prognostic significance of Ki-67 antigen expression in non-Hodgkin's lymphomas. Anticancer Res 2008, 28:1113–1118.
- Lapela M, Leskinen S, Minn HR, . Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 1995;86:3522–3527.
- Schoder H, Noy A, Gonen M, . Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 2005;23:4643–4651.
- Hutchings M, Specht L. PET/CT in the management of haematological malignancies. Eur J Haematol 2008;80:369–380.
- Wu X, Dastidar P, Pertovaara H, . Early Treatment Response Evaluation in Patients with Diffuse Large B-Cell Lymphoma-A Pilot Study Comparing Volumetric MRI and PET/CT. Mol Imaging Biol 2011;13:785–792.
- Rosenberg SA. Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas. Cancer Treat Rep 1977;61:1023–1027.
- A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–994.
- Wilder RB, Rodriguez MA, Medeiros LJ, . International prognostic index-based outcomes for diffuse large B-cell lymphomas. Cancer 2002;94:3083–3088.
- WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th Edition. Vol 2 of the WHO series on histological and genetic typing of human tumours Edited by Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J., Vardiman, J.W. IARC, Lyon 2008.
- Weber G. Enzymology of cancer cells (first of two parts). N Engl J Med 1977;296:486–492.
- Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029–1033.
- Okada J, Yoshikawa K, Itami M, . Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 1992;33:325–329.
- Watanabe R, Tomita N, Takeuchi K, . SUVmax in FDG-PET at the biopsy site correlates with the proliferation potential of tumor cells in non-Hodgkin lymphoma. Leuk Lymphoma 2010;51:279–283.
- Papajik T, Myslivecek M, Sedova Z, . Standardised uptake value of 18F-FDG on staging PET/CT in newly diagnosed patients with different subtypes of non-Hodgkin's lymphoma. Eur J Haematol 2011;86:32–37.
- Tang B, Malysz J, Douglas-Nikitin V, . Correlating metabolic activity with cellular proliferation in follicular lymphomas. Mol Imaging Biol 2009;11:296–302.
- Bodet-Milin C, Kraeber-Bodere F, Moreau P, . Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma. Haematologica 2008;93:471–472.
- Noy A, Schoder H, Gonen M, . The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). Ann Oncol 2009;20:508–512.
- Wu X, Korkola P, Pertovaara H, . No correlation between glucose metabolism and apparent diffusion coefficient in diffuse large B-cell lymphoma: A PET/CT and DW-MRI study. Eur J Radiol 2011;79:e117–121.